Clinical Trial Update: A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a booster dose of MenACWY-TT (Nimenrix) given 10 years after initial vaccination in healthy 11-17-year-olds; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Acwy Disease
• Meningococcal Disease

Drugs mentioned

• MenACWY-TT (Nimenrix) (MenACWY-TT)
• Mencevax ACWY

Snippet

Sponsor: Pfizer | Conditions: Meningococcal ACWY Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-10-12